ProfileGDS5678 / 1448894_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 91% 91% 84% 92% 87% 87% 88% 88% 93% 93% 91% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.5439592
GSM967853U87-EV human glioblastoma xenograft - Control 27.4821891
GSM967854U87-EV human glioblastoma xenograft - Control 37.3674791
GSM967855U87-EV human glioblastoma xenograft - Control 46.4403184
GSM967856U87-EV human glioblastoma xenograft - Control 57.7005692
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3871987
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4711687
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.7398788
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8311788
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.9485293
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.9015793
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.5351391
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.9016993
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9142593